News

Calculus Capital Limited and Polar Capital LLP to join share register

C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery engine, today announces that it has raised £5.0 million before expenses (the "Placing") via a conditional placing of 4,901,961 new ordinary shares (the "Placing Shares") to current and new investors, through Zeus Capital as nominated adviser and broker to the Company, at a placing price of 102p (the “Placing Price”) per ordinary share.

The company has acquired “a virtual library of over a billion molecules”, which should give the company a boost when it starts new discovery programmes.

According to Dr Clive Dix, the chief executive officer of C4X, the newly acquired software is “all about optimising those molecules that we find by using our other technologies”.

Dr Dix told Proactive Investors: “Everything we do is aimed at reducing the time and the cost of getting to the clinical trial and then … with the molecules we have being of higher quality, they’ll be more likely to be successful in the trials.”
The company will be starting new projects on a regular basis and when the time is right will decide on a case-by-case basis whether to bring in a partner or take the drugs to clinical trial independently.

Proprietary platform technology further augments C4X Discovery’s drug discovery engine

12th July, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the acquisition of a suite of advanced drug-discovery technologies from MolPlex Ltd (the "Molplex Technologies").

Taxonomy 3 analyses publicly available databases to identify previously unknown linkages between genes and diseases.

C4X Discovery Holdings (LON:C4XD) chief executive Clive Dix said the company had studied rheumatoid arthritis and Parkinson's disease data. "What we have found are genes that are highly associated with these diseases."

~ Rapid progress with drug discovery portfolio and ground-breaking findings in inflammation and neurodegeneration ~

4th July, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the identification of multiple new drug targets in the areas of inflammation and neurodegeneration.

4th May, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces that Clive Dix has been appointed Chief Executive Officer with immediate effect.

Two health and life science businesses funded by Innovate UK have come together to create a powerful way to find and design new drugs.

Thursday, 17 March 2016

Press Release Interim Results

17 March, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces its interim unaudited results for the six months ended 31 January 2016.

Corporate highlights

  • Dr Clive Dix appointed as Executive Chairman to implement strategy of building the world’s most productive drug discovery and development company.
  • Significant progress across therapeutic programmes:
    • Addiction: oral drug candidate from the Orexin-1 programme for the treatment of addictive disorders such as nicotine addiction, continues to progress through preclinical development. Potential imaging agent for planned Phase I study identified. Second, differentiated Orexin-1 antagonist identified as follow-up candidate.
    • Inflammation: design of novel oral activators of the NRF-2 pathway which is important in lung diseases with high unmet medical need such as Chronic Obstructive Pulmonary Disease (“COPD”); identification of small molecule inhibitors of the IL-17 pathway implicated in multiple inflammatory and autoimmune diseases including psoriasis.
    • Diabetes: identification of novel, potent, orally available lead molecules activating GPR142 a key factor in the production of insulin.
  • Collaboration established with University of Oxford’s Structural Genomics Consortium (“SGC-Oxford”) to improve and identify potent and selective molecules against a range of targets and initiation of an oncology therapeutic programme.
  • Refinement of hybrid business model of wholly owned pipeline of drug discovery programmes plus partnerships with Pharma and Biotech. Access to C4XD proprietary technologies on a fee for service basis to be discontinued to maximise internal resource available for value creating pipeline projects. Aim to transition current fee-for-service relationships to shared IP or milestone driven collaborative agreements.